Compare Anheuser-Busch Inbev SA (BUD) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs DexCom, Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $78.99 (market cap $159.01B), while DexCom, Inc. trades at $89.14 (market cap $33.79B). The key difference: Anheuser-Busch Inbev SA is far larger — about 4.7× DexCom, Inc.'s market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| BUD | DXCM | |
|---|---|---|
Market Cap | $159.01B | $33.79B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $89.53 |
52-Week Low | $57.93 | $54.84 |
Enterprise Value | $223.42B | $33.24B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.
The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
